TeloB-Vax is an important asset in Adamis' oncology pipeline. The technology forming the basis for the patent was discovered and developed by
These technologies constitute the basis of a novel cell-based cancer vaccine product candidate, TeloB-VAX, which has been shown to activate the body's natural defense system to stimulate an immune response against one of cancer's most common tumor markers, telomerase. The vaccine utilizes the patient's own B cells as antigen producing and antigen presenting cells. The B cells present telomerase peptides to the T cells that then expand and search out and kill prostate cancer cells.
Dr. Zanetti has said of the TeloB-Vax vaccine technology, "It may represent one of the first concrete opportunities to program the immune system to induce killer lymphocytes to combat cancer cells, whether these are adult differentiated cells or progenitor cancer stem cells. Since telomerase is increased in over 85% of all cancers, the vaccine could potentially be used to treat multiple cancer types, such as breast, lung, and colon cancer. I believe that it can truly be considered a platform therapeutic vaccine technology." Telomerase was the subject of the Nobel Prize for Medicine in 2009.
Adamis' TeloB-VAX vaccine technology is composed of the patient's own circulating B lymphocytes harboring a unique patented engineered plasmid DNA. The transfection procedure is "spontaneous," requiring no facilitating molecules or devices. After 60 minutes of incubation with the plasmid, the patient's own cells can be re-infused.
In a Phase 1 study already completed at UCSD in castrate resistant prostate cancer patients, the vaccine product was shown to be safe, non-toxic and immunogenic. Two injections of TeloB-VAX, spaced one month apart, was shown to induce a specific CD8 T cell response. More important, the T cells were shown to specifically kill prostate cancer cells.
Recent, previously-reported developments include the following:
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws that relate to future events or our future results of operations, including, but not limited to the following statements: our ability to successfully develop the TeloB-VAX product candidate or any other product candidate; the safety, efficacy or therapeutic impact of any product candidate that we may develop; our ability to fund future product development and business operations; the intellectual property protection that may be afforded by any patents or patent applications relating to the company's technology; and the results of any future preclinical or clinical trials that may be conducted concerning TeloB-VAX or any other product candidate. Forward looking statements involve risks and uncertainties, and are not guarantees of future performance. Actual events or results may differ materially from those contemplated by such forward looking statement. Forward looking statements assume that we will have sufficient funding to support the activities contemplated by such forward looking statements and that there are no significant unexpected developments or events that delay or prevent such activities from occurring. There can be no assurance that this will be the case. You should not place undue reliance on any forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the
Mark FlatherDirector, Investor Relations & Corporate Communications Adamis Pharmaceuticals Corporation(858) 412-7951 firstname.lastname@example.org Mark Gundy Capital Group Communications, Inc.(972) 240-1873 email@example.com